{
    "analytics_identifier":  null,
    "base_path":  "/guidance/converting-centrally-authorised-products-caps-to-uk-marketing-authorisations-mas-grandfathering-and-managing-lifecycle-changes",
    "content_id":  "8fa70744-6820-4b33-9823-25ece606ff94",
    "description":  "This guidance covers ‘grandfathering’ and managing the lifecycle changes of medicinal products.",
    "details":  {
                    "attachments":  [
                                        {
                                            "accessible":  false,
                                            "alternative_format_contact_email":  "webupdates@mhra.gov.uk",
                                            "attachment_type":  "file",
                                            "content_type":  "application/pdf",
                                            "file_size":  46308,
                                            "filename":  "summary_variations_table_pdf.pdf",
                                            "id":  "5741557",
                                            "number_of_pages":  4,
                                            "title":  "Summary approach to variations",
                                            "url":  "https://assets.publishing.service.gov.uk/media/5feded848fa8f53b7e43fc71/summary_variations_table_pdf.pdf"
                                        }
                                    ],
                    "body":  "\u003cdiv class=\"govspeak\"\u003e\u003cp\u003eThe Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s stand-alone medicines and medical devices regulator, taking any decisions and carrying out any functions which were taken or carried out at \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e-level except for decisions on Marketing Authorisation (\u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e) applications made through the European procedures to market products in Northern Ireland.\u003c/p\u003e\n\n\u003ch2 id=\"general-approach-to-grandfathering-of-caps\"\u003eGeneral approach to grandfathering of \u003cabbr title=\"Centrally Authorised Products\"\u003eCAPs\u003c/abbr\u003e\n\u003c/h2\u003e\n\n\u003cp\u003eAll existing \u003cabbr title=\"Centrally Authorised Product\"\u003eCAP\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e have been automatically converted into UK \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e effective in Great Britain (only) and issued with a UK \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e number on 1 January 2021. These UK \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e are referred to in this guidance as “converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e”. As a result of the implementation of the Northern Ireland Protocol, existing \u003cabbr title=\"Centrally Authorised Products\"\u003eCAPs\u003c/abbr\u003e will remain valid for marketing products in Northern Ireland.\u003c/p\u003e\n\n\u003cp\u003e\u003cabbr title=\"Marketing Authorisation Holders\"\u003eMAHs\u003c/abbr\u003e can choose to opt-out of the conversion process for all or some of their \u003cabbr title=\"Centrally Authorised Products\"\u003eCAPs\u003c/abbr\u003e by notifying the MHRA in writing following which those UK \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e will be revoked. To opt out you must let the MHRA know by the end of 21 January 2021.\u003c/p\u003e\n\n\u003cp\u003e\u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e for \u003cabbr title=\"Centrally Authorised Products\"\u003eCAPs\u003c/abbr\u003e that are not currently marketed in the \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e or UK can still be converted to Great Britain \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e. For the purposes of operating the Sunset Clause in accordance with regulation 67 Human Medicines Regulations 2012 (as amended), the period of three years during which the product has not been marketed in Great Britain will be restarted from the date of conversion to a Great Britain \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e.\u003c/p\u003e\n\n\u003cp\u003eTo facilitate the grandfathering process, the MHRA will issue one or more Product Licence (\u003cabbr title=\"Product License\"\u003ePL\u003c/abbr\u003e) numbers to \u003cabbr title=\"Centrally Authorised Products\"\u003eCAPs\u003c/abbr\u003e based on the existing UK practice for determining how many separate national licences are needed across a product range. In most cases this means that fewer UK \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e numbers will be needed in comparison with the number of European Commission authorisations because all pack sizes for a presentation will be covered by a single \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e number.\u003c/p\u003e\n\n\u003cp\u003eThe format of the UK \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e valid only in Great Britain will be PLGB XXXXX/YYYY where XXXXX is the company number and YYYY is a sequential number for individual products. Where a \u003cabbr title=\"Centrally Authorised Product\"\u003eCAP\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation Holder\"\u003eMAH\u003c/abbr\u003e already has a company number allocated by MHRA for existing national licences, that number will be used. If the \u003cabbr title=\"Centrally Authorised Product\"\u003eCAP\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation Holder\"\u003eMAH\u003c/abbr\u003e does not have a company number allocated by MHRA then an application form for a number will be required.\u003c/p\u003e\n\n\u003cp\u003eThere is no fee associated with the conversion from a \u003cabbr title=\"Centrally Authorised Product\"\u003eCAP\u003c/abbr\u003e to a Great Britain \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e.\u003c/p\u003e\n\n\u003cp\u003eIf the \u003cabbr title=\"Marketing Authorisation Holder\"\u003eMAH\u003c/abbr\u003e chooses to opt-out, their product(s) will no longer be licensed and must not be marketed in Great Britain. The MHRA will publish a list of products that have and have not been converted as a result of this exercise.\u003c/p\u003e\n\n\u003cp\u003eTo support the ongoing regulation of these converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e, the MHRA needs essential baseline data to be submitted in the form of an initiating electronic Common Technical Document (\u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e) sequence together with certain other related \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e-specific information for each converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e.\u003c/p\u003e\n\n\u003cp\u003e\u003cabbr title=\"Marketing Authorisation Holders\"\u003eMAHs\u003c/abbr\u003e will have a period of one year starting on 1 January 2021 to submit this data and related information in \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e format. Until these initiating sequences are submitted and processed, it will not be possible to submit a variation for the converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e unless there are exceptional circumstances relating to public health. There is no fee for the grandfathering process.\u003c/p\u003e\n\n\u003cp\u003eAs with all national \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e, an \u003ca href=\"https://www.gov.uk/government/publications/mhra-fees/current-mhra-fees\" class=\"govuk-link\"\u003eannual service fee\u003c/a\u003e will be due for converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e from 1 April 2021 unless the \u003cabbr title=\"Marketing Authorisation Holder\"\u003eMAH\u003c/abbr\u003e opts out by the required date.\u003c/p\u003e\n\n\u003ch2 id=\"actions-that-holders-of-converted-eu-mas-need-to-take\"\u003eActions that holders of converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e need to take\u003c/h2\u003e\n\n\u003ch2 id=\"what-to-submit-in-the-initiating-sequence-and-other-related-information\"\u003e1. What to submit in the initiating sequence and other related information\u003c/h2\u003e\n\n\u003cp\u003eWithin the period of one year starting on 1 January 2021, the \u003cabbr title=\"Marketing Authorisation Holder\"\u003eMAH\u003c/abbr\u003e must submit the following information to the MHRA for each converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e. (This is the information which is specified in paragraph 9(3)(a) of new Schedule 33A to the Human Medicines Regulations 2012, as inserted by the Human Medicines (Amendment etc.) (\u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e Exit) Regulations 2019).\u003c/p\u003e\n\n\u003cp\u003eThe data submission package must contain:\u003c/p\u003e\n\n\u003cp\u003ea) cover letter and declaration that only approved documentation is included in the initiating sequence. The cover letter should clearly identify the submission as a “\u003cabbr title=\"Centrally Authorised Product\"\u003eCAP\u003c/abbr\u003e Grandfathering Submission” in the title. The cover letter should also confirm whether a nitrosamine risk evaluation has been submitted in accordance with the \u003cabbr title=\"Committee for Medicinal products for Human Use\"\u003eCHMP\u003c/abbr\u003e opinion under Article 5 (3) of Regulation (EC) No. 726/2004 on the presence of nitrosamine impurities in human medicinal products, or whether it is pending. If already submitted, the conclusion of the risk evaluation should be stated.\u003c/p\u003e\n\n\u003cp\u003eb) a single \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e initiating sequence for the converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e representing the currently authorised and approved position. Where more than one dosage form or strength will be converted for the same product trade name, it is expected these will be handled as one \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e dossier. If the product dossier refers to an Active Substance Master File, the \u003cabbr title=\"Marketing Authorisation Holder\"\u003eMAH\u003c/abbr\u003e must ask the active substance supplier to submit that to MHRA if they have not already done so. We have published guidance on how to do this\u003c/p\u003e\n\n\u003cp\u003ec) a completed electronic application form (\u003cabbr title=\"electronic Application Form\"\u003eeAF\u003c/abbr\u003e) for each converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e.\u003c/p\u003e\n\n\u003cp\u003ed) a summary list of all historical regulatory activity from the grant date of the original \u003cabbr title=\"Centrally Authorised Product\"\u003eCAP\u003c/abbr\u003e until the data is submitted. This will include:\u003c/p\u003e\n\n\u003cp\u003eI. type of submission (such as initial new Marketing Authorisation Applications (\u003cabbr title=\"Marketing Authorisation Applications\"\u003eMAA\u003c/abbr\u003e), Variation, Periodic Safety Update Report (\u003cabbr title=\"Periodic Safety Update Report\"\u003ePSUR\u003c/abbr\u003e), Renewal)\u003c/p\u003e\n\n\u003cp\u003eII. the date of submission to the European Medicines Agency (\u003cabbr title=\"European Medicines Agency\"\u003eEMA\u003c/abbr\u003e) (optional if the outcome date is available)\u003c/p\u003e\n\n\u003cp\u003eIII. summary of the submission (such as a short description of a variation)\u003c/p\u003e\n\n\u003cp\u003eIV. regulatory outcome (such as granted or not granted)\u003c/p\u003e\n\n\u003cp\u003eV. the date of the outcome\u003c/p\u003e\n\n\u003cp\u003eVI. \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e sequence number of the submission (only for \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e format submissions)\u003c/p\u003e\n\n\u003cp\u003eAlternatively, the historical document can mirror the format of the \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e procedural steps document if this makes it easier to create.\u003c/p\u003e\n\n\u003cp\u003ee) notification of whether or not the product referred to in the converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e is on the Great Britain market at the time the notification is given. If it is not, the \u003cabbr title=\"Marketing Authorisation Holder\"\u003eMAH\u003c/abbr\u003e must tell us whether the product has been on the Great Britain market at any time after 1 January 2021 and, if so, the date it was withdrawn from the market (for the purposes of Article 23a and Article 24 (4-6) of Directive 2001/83EC – as implemented in regulations 67 and 73 of the Human Medicines Regulations 2012), the “Sunset Clause”). This information may be included in the cover letter. .\u003c/p\u003e\n\n\u003cp\u003ef) the Summary of Product Characteristics (\u003cabbr title=\"Summary of Product Characteristics\"\u003eSmPC\u003c/abbr\u003e) currently approved by corresponding \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e procedure both in pdf format and in the \u003ca rel=\"external\" href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/786333/SPC_template.docx\" class=\"govuk-link\"\u003eSPC template\u003c/a\u003e\u003c/p\u003e\n\n\u003cp\u003eg) the packaging labels and leaflets as currently approved by the corresponding \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e procedure which are:\u003c/p\u003e\n\n\u003cp\u003eI. the outer packaging of the medicinal product;\u003c/p\u003e\n\n\u003cp\u003eII. the immediate packaging of the medicinal product; and\u003c/p\u003e\n\n\u003cp\u003eIII. the package leaflet for the medicinal product.\u003c/p\u003e\n\n\u003ch2 id=\"what-to-submit-if-the-converted-licence-should-be-cancelled-in-mainland-uk-between-31-december-2020-and-31-december-2021\"\u003e2. What to submit if the converted licence should be cancelled in mainland UK between 31 December 2020 and 31 December 2021\u003c/h2\u003e\n\n\u003cp\u003e\u003cabbr title=\"Marketing Authorisation Holders\"\u003eMAHs\u003c/abbr\u003e will have a period of one year starting on 1 January 2021 to submit the data and related information in \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e format for all converted licences. If an application is not submitted before 31 December 2021 the licence will be considered to be cancelled.\u003c/p\u003e\n\n\u003cp\u003eAny converted Centralised licence that is required on the UK market but has not had a submission made before the 31 December 2021 can only be re-registered through submission of a new application to the MHRA at the normal cost and will require a new assessment to be completed prior to marketing the product.\u003c/p\u003e\n\n\u003cp\u003eIf a converted licence is to be cancelled in mainland UK, the MHRA requests that a basic submission (see below for requirements) is made with a request to cancel the \u003cabbr title=\"Centrally Authorised Product\"\u003eCAP\u003c/abbr\u003e licence which will be processed after basic licence details have been recorded. This will allow the MHRA database to have a record for all licences that were converted to national licences on 1 January 2021. Any licences cancelled by \u003cabbr title=\"European Medicines Agency\"\u003eEMA\u003c/abbr\u003e before 31 December 2020 do not need to be registered.\u003c/p\u003e\n\n\u003ch3 id=\"what-to-submit-for-a-converted-licence-that-should-be-cancelled-before-1-january-2022\"\u003eWhat to submit for a converted licence that should be cancelled before 1 January 2022\u003c/h3\u003e\n\u003cp\u003eThe data submission package must contain:\u003c/p\u003e\n\n\u003cp\u003ea) a single \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e initiating sequence for the converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e(s) containing the following documents. Where more than one dosage form or strength is converted for the same product trade name, it is expected these will be handled as one \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e dossier.\u003c/p\u003e\n\n\u003cp\u003eb) cover letter The cover letter should clearly identify the submission as a “\u003cabbr title=\"Centrally Authorised Product\"\u003eCAP\u003c/abbr\u003e Grandfathering Submission” in the title and include the statement that the licence should be cancelled in mainland UK.\nc) a completed electronic application form (\u003cabbr title=\"electronic Application Form\"\u003eeAF\u003c/abbr\u003e) for each converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e.\u003c/p\u003e\n\n\u003cp\u003ed) the Summary of Product Characteristics (\u003cabbr title=\"Summary of Product Characteristics\"\u003eSmPC\u003c/abbr\u003e) currently approved by corresponding \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e procedure both in pdf format and in the SPC template\u003c/p\u003e\n\n\u003cp\u003ee) the packaging labels and leaflets as currently approved by the corresponding \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e procedure which are:\u003c/p\u003e\n\n\u003cp\u003eI. the outer packaging of the medicinal product;\u003c/p\u003e\n\n\u003cp\u003eII. the immediate packaging of the medicinal product; and\u003c/p\u003e\n\n\u003cp\u003eIII. the package leaflet for the medicinal product.\u003c/p\u003e\n\n\u003cp\u003eIf a \u003cabbr title=\"Centrally Authorised Product\"\u003eCAP\u003c/abbr\u003e submission has been made before November but an approval letter has not been received by 1 December please contact the Customer service team who will be able to ensure the application is completed before the deadline.\u003c/p\u003e\n\n\u003ch2 id=\"further-advice-on-documentation\"\u003e3. Further advice on documentation\u003c/h2\u003e\n\n\u003cp\u003eThe summary of historical regulatory activity (section d above) must be included in the Working Documents folder of the \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e and the notification of marketing status (section e above) must be included in the cover letter.\u003c/p\u003e\n\n\u003cp\u003eThe cover letter, electronic Application Form (\u003cabbr title=\"electronic Application Form\"\u003eeAF\u003c/abbr\u003e) and currently approved \u003cabbr title=\"Summary of Product Characteristics\"\u003eSmPC\u003c/abbr\u003e, Packaging and Patient Information Leaflet (\u003cabbr title=\"Patient Information Leaflet\"\u003ePIL\u003c/abbr\u003e) must be included in the appropriate folders in Module 1 of the \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e sequence.\u003c/p\u003e\n\n\u003cp\u003eThe submission must reflect only what is relevant to the product intended for Great Britain so that this can be used as the start of the lifecycle for the nationally registered product(s). Inclusion of non-UK specific information could, over time, lead to inaccurate information held within the database and may lead to difficulties with the technical validation of subsequent submissions.\u003c/p\u003e\n\n\u003cp\u003eThe \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e sequence must pass technical validation (sections 4 and 5 below). The MHRA will apply an abbreviated content validation and will not issue a validation report, the presence of a \u003cabbr title=\"Summary of Product Characteristics\"\u003eSmPC\u003c/abbr\u003e, \u003cabbr title=\"Patient Information Leaflet\"\u003ePIL\u003c/abbr\u003e and packing information are mandatory.\u003c/p\u003e\n\n\u003cp\u003eThe MHRA expects that all information representing the currently authorised and approved position that has previously been submitted in \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e format will be included in the initiating sequence submission. However, it is acknowledged that some information may not be available in electronic format, particularly for older products, and that it may not be possible for the initiating sequence to be entirely complete.\u003c/p\u003e\n\n\u003cp\u003eIn these circumstances, the \u003cabbr title=\"Marketing Authorisation Holder\"\u003eMAH\u003c/abbr\u003e should submit what is available and the MHRA will accept a partially completed sequence, provided:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eThe \u003cabbr title=\"Marketing Authorisation Holder\"\u003eMAH\u003c/abbr\u003e makes all reasonable endeavours to include any information available in an electronic format other than \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e format, in the appropriate \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e structure in accordance with \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e technical validation criteria.  Avoid placing documents in the Working Documents section of the \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e structure and use it by exception only.\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eThe holder of the converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e responds to a request to provide any information related to the \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e either before or after submission of the initiating sequence, including historical information, within the time period specified in the request.\u003c/p\u003e\n\n\u003ch2 id=\"how-to-submit-the-application\"\u003e4. How to submit the application\u003c/h2\u003e\n\n\u003cp\u003eExcept for applications made through European procedures to market in Northern Ireland, the MHRA does not expect to be able to receive submissions through the Common European Submission Portal (\u003cabbr title=\"Common European Submission Portal\"\u003eCESP\u003c/abbr\u003e). We have developed a new national portal  and submissions will be made via this portal.\u003c/p\u003e\n\n\u003ch2 id=\"specific-advice-on-preparing-the-initiating-sequence\"\u003e5. Specific advice on preparing the initiating sequence\u003c/h2\u003e\n\u003cp\u003eBackground information on the latest version of the \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e standard, including \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e guidance on Module 1 information and the electronic application form \u003ca rel=\"external\" href=\"http://esubmission.ema.europa.eu/ectd/\" class=\"govuk-link\"\u003ecan be found on the \u003cabbr title=\"European Medicines Agency\"\u003eEMA\u003c/abbr\u003e e-submissions website\u003c/a\u003e.\u003c/p\u003e\n\n\u003cp\u003eThe date on which the minimal or full initiating sequence is received is referred to as “the data submission date”. The \u003cabbr title=\"Marketing Authorisation Holder\"\u003eMAH\u003c/abbr\u003e should construct a single, technically valid, \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e sequence (the “Converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e Initiating Sequence”) showing the current, approved information (“current authorised view”) of the converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e(s) on the data submission date.\u003c/p\u003e\n\n\u003cp\u003eInformation that has been “replaced” or “deleted” during the life cycle of the \u003cabbr title=\"Centrally Authorised Product\"\u003eCAP\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e that the converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e is derived from should not be included.\u003c/p\u003e\n\n\u003cp\u003eThe sequence should be assigned as sequence number 0000, submission type “\u003cabbr title=\"Marketing Authorisation Applications\"\u003emaa\u003c/abbr\u003e” and submission unit assigned as “initial”.\u003c/p\u003e\n\n\u003cp\u003ePoints to consider:\u003c/p\u003e\n\n\u003cp\u003ea) Only include Great Britain relevant information. Remove previous cover letters and application forms, and remove all product information except Great Britain specific information.\u003c/p\u003e\n\n\u003cp\u003eb)  Remove all \u003cabbr title=\"Periodic Safety Update Report\"\u003ePSUR\u003c/abbr\u003e information. \u003cabbr title=\"Periodic Safety Update Reports\"\u003ePSURs\u003c/abbr\u003e will not need to be submitted in the \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e lifecycle.\u003c/p\u003e\n\n\u003cp\u003ec) Historical \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e information about the \u003cabbr title=\"Pharmacovigilance\"\u003ePV\u003c/abbr\u003e Master File, etc. in module 1.8. is not required. New information must be submitted as a later type IA variation.\u003c/p\u003e\n\n\u003cp\u003ed) Remove all responses to questions in module 1 - i.e. remove any discussion and only show the outcome in terms of the documents in the rest of modules 1-5.\u003c/p\u003e\n\n\u003cp\u003ee) The submission must include a full \u003cabbr title=\"electronic Application Form\"\u003eeAF\u003c/abbr\u003e) for each of the products in the application. The “Initial \u003cabbr title=\"Marketing Authorisation Applications\"\u003eMAA\u003c/abbr\u003e” \u003cabbr title=\"electronic Application Form\"\u003eeAF\u003c/abbr\u003e should be used with the initiating sequence and only approved information should be included - any changes to the approved information must be submitted as a variation after the submission of the initiating sequence using the normal process for variations to national \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e (see information on variations in sections 6 - 8).\u003c/p\u003e\n\n\u003cp\u003ef) The summary of historical regulatory activity must begin with the original \u003cabbr title=\"Centrally Authorised Product\"\u003eCAP\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation Applications\"\u003eMAA\u003c/abbr\u003e submission and continue up to the data submission date. This must be a list of the submission events in a table format, not the individual \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e sequences that were submitted for each event (noting that for some products these events will predate the \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e). Please submit this in the same format as the tracking table in module 1.0.\u003c/p\u003e\n\n\u003cp\u003eg) The initiating sequence must be a valid \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e submission, built to \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e module 1 v3.0.2 and \u003cabbr title=\"International Council for Harmonisation\"\u003eICH\u003c/abbr\u003e v3.2.2 standards or, if these are superseded, by such standards that are applicable at the time of submission. Non-functioning hyperlinks are acceptable if they are unavoidable.\u003c/p\u003e\n\n\u003cp\u003eh) The initiating sequence should include multiple dosage forms and strengths in a single \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e dossier lifecycle.\u003c/p\u003e\n\n\u003ch2 id=\"submitting-the-initiating-sequence-in-two-steps\"\u003e6.\tSubmitting the initiating sequence in two steps\u003c/h2\u003e\n\n\u003cp\u003eThe MHRA strongly prefers \u003cabbr title=\"Marketing Authorisation Holders\"\u003eMAHs\u003c/abbr\u003e submit the initiating sequence as a single event. However, it is recognised that some \u003cabbr title=\"Marketing Authorisation Holders\"\u003eMAHs\u003c/abbr\u003e may need to submit variations, renewals or Article 61(3) notifications to the \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e before they can produce the complete initiating sequence.\u003c/p\u003e\n\n\u003cp\u003eIn these circumstances, the \u003cabbr title=\"Marketing Authorisation Holder\"\u003eMAH\u003c/abbr\u003e can use a two-step process by first submitting a minimal initiating sequence containing at least the mandatory documents at an early point following 1 January 2021.\u003c/p\u003e\n\n\u003cp\u003eThe mandatory documents are:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ethose described in section 1f) and 1g)\u003c/li\u003e\n  \u003cli\u003ean \u003cabbr title=\"electronic Application Form\"\u003eeAF\u003c/abbr\u003e containing at least the mandatory information (as defined in the \u003cabbr title=\"electronic Application Form\"\u003eeAF\u003c/abbr\u003e section 1c))\u003c/li\u003e\n  \u003cli\u003ea cover letter and declaration (see section 1a)).\u003c/li\u003e\n  \u003cli\u003ea statement in the cover letter that this is a minimal initiating sequence and commitment to send the complete initiating sequence within a period of one year starting on 1 January 2021.\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eThe sequence must also be technically valid (see section 4g) above).\u003c/p\u003e\n\n\u003cp\u003eIf \u003cabbr title=\"Marketing Authorisation Holders\"\u003eMAHs\u003c/abbr\u003e take this approach, a further complete initiating sequence, containing all documents electronically and the specific other related information defined in section 2, must still be submitted within a period of one year starting on 1 January 2021. The sequence number of this submission should be sequential to the earlier minimal initiating sequence and any subsequent variations or other submissions.\u003c/p\u003e\n\n\u003cp\u003eIf \u003cabbr title=\"Marketing Authorisation Holders\"\u003eMAHs\u003c/abbr\u003e submit an early minimal initiating sequence we advise making every effort to include Module 3 (quality) documents. This module is frequently varied and, if the documents are not available, any subsequent variation to M3 is likely to be delayed by the need to request missing data.\u003c/p\u003e\n\n\u003ch2 id=\"general-approach-to-variations-to-converted-eu-mas-from-1-january-2021\"\u003e7.\tGeneral approach to variations to converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e from 1 January 2021\u003c/h2\u003e\n\n\u003cp\u003eIn general, the MHRA will not consider variations to converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e before at least a minimal initiating sequence (as defined in section 5) and related documentation (the “data submission package”) have been submitted. The date on which the minimal or full initiating sequence is received is referred to as the data submission date.\u003c/p\u003e\n\n\u003cp\u003eIn exceptional circumstances, we may consider a variation before the data submission date if, in our view, the following circumstances apply:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ethe variation is necessary on urgent safety grounds\u003c/li\u003e\n  \u003cli\u003ethe variation is necessary in order to maintain supplies of a particular medicinal product to patients in Great Britain\u003c/li\u003e\n  \u003cli\u003ethere are other necessary or beneficial reasons for considering the variation in advance of receipt of the baseline information\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eIf the holder of a converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e considers that these conditions may apply, they should contact the agency’s \u003ca href=\"https://www.gov.uk/guidance/contact-mhra#regulatory-information-service-ris\" class=\"govuk-link\"\u003eRegulatory Information Service\u003c/a\u003e to ask for agreement from MHRA and discuss how to proceed.\u003c/p\u003e\n\n\u003cp\u003eVariation applications may be included with the data submission package as separate \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e sequences in line with the normal national \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e variation process. However the variation will only be considered after the baseline is processed and will be treated as if it was submitted after the data submission date.\u003c/p\u003e\n\n\u003cp\u003eThe table at the bottom of this page provides a summary of the approach to variations that MHRA will take in the different scenarios which may arise.\u003c/p\u003e\n\n\u003ch2 id=\"approach-to-variations-submitted-to-the-ema-but-not-granted-before-1-january-2021\"\u003e8.\tApproach to variations submitted to the \u003cabbr title=\"European Medicines Agency\"\u003eEMA\u003c/abbr\u003e but not granted before 1 January 2021\u003c/h2\u003e\n\n\u003cp\u003eTo simplify handling of variation submissions the MHRA has adopted a pragmatic approach to these submissions.\u003c/p\u003e\n\n\u003ch3 id=\"type-ia-and-type-ib-variations\"\u003eType IA and Type IB Variations\u003c/h3\u003e\n\n\u003cp\u003eFor minor variations of Type IA and Type 1B, these may be implemented in relation to the converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e at the same time as they are implemented in relation to the corresponding \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e. The variation must be included in the initiating sequence submission as if it had already been accepted in Great Britain.\u003c/p\u003e\n\n\u003cp\u003eThe \u003cabbr title=\"Marketing Authorisation Holder\"\u003eMAH\u003c/abbr\u003e must inform the MHRA when submitting the sequence if the variation was rejected or refused by the \u003cabbr title=\"European Medicines Agency\"\u003eEMA\u003c/abbr\u003e after 1 January 2021 but before the data submission date, and the variation must be removed from the initiating sequence.\u003c/p\u003e\n\n\u003cp\u003eThe variations will be deemed to be accepted unless the holder of the converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e is notified, within 30 days of the data submission date, that it has been rejected.\u003c/p\u003e\n\n\u003cp\u003eThe details of the variations must be included in the summary of historical regulatory activity submitted with the initiating sequence\u003c/p\u003e\n\n\u003ch3 id=\"type-ii-variations\"\u003eType II Variations\u003c/h3\u003e\n\n\u003cp\u003eFor major variations of type II, if the variation had reached positive Committee for Medicinal products for Human Use (\u003cabbr title=\"Committee for Medicinal products for Human Use\"\u003eCHMP\u003c/abbr\u003e) opinion stage before 1 January 2021:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ethe variation must be included within the initiating sequence submission as if it had already been accepted in Great Britain\u003c/li\u003e\n  \u003cli\u003ethe variation may be implemented in relation to the converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e at the same time as it is implemented in relation to the corresponding \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e\n\u003c/li\u003e\n  \u003cli\u003ethe details of the type II variation must be included in the summary of historical regulatory activity submitted with the initiating sequence\u003c/li\u003e\n  \u003cli\u003eno fee will apply for these variations\u003c/li\u003e\n  \u003cli\u003ethe MHRA will notify the holder of the converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e marketing authorisation within 30 days beginning with the data submission date if the variation is rejected, in which case the holder must cease to apply the rejected variation immediately after receipt of the notification.\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eIf the Type II variation had not reached \u003cabbr title=\"Committee for Medicinal products for Human Use\"\u003eCHMP\u003c/abbr\u003e opinion and at 1 January 2021 was in clock-stop following a request for further information:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ea copy of the variation application must be included in the data submission package as a separate \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e sequence (sequence 0001 and so on)\u003c/li\u003e\n  \u003cli\u003ethe variation will only be considered after the initiating sequence is processed.\u003c/li\u003e\n  \u003cli\u003eno fee will apply for these variations. Great Britain will review responses when submitted.\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eIf the Type II variation had not reached \u003cabbr title=\"Committee for Medicinal products for Human Use\"\u003eCHMP\u003c/abbr\u003e opinion and at 1 January 2021 was before clock-stop:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ea copy of the variation application must be included in the data submission package as a separate \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e sequence (sequence 0001 and so on).\u003c/li\u003e\n  \u003cli\u003ethe variation will only be considered after the initiating sequence is processed.\u003c/li\u003e\n  \u003cli\u003ethe \u003ca href=\"https://www.gov.uk/government/publications/mhra-fees/current-mhra-fees\" class=\"govuk-link\"\u003eappropriate fee will apply\u003c/a\u003e for these variations and the variation will be reviewed by MHRA.\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eIf the applicant wishes for the variation to be put on hold pending finalisation by the \u003cabbr title=\"European Medicines Agency\"\u003eEMA\u003c/abbr\u003e, this should be clearly indicated in the cover letter of each relevant variation, either at the time of initial submission or where relevant the submission of the responses to the MHRA.\u003c/p\u003e\n\n\u003cp\u003eWhen the procedure has been positively concluded by the \u003cabbr title=\"European Medicines Agency\"\u003eEMA\u003c/abbr\u003e or a positive \u003cabbr title=\"Committee for Medicinal products for Human Use\"\u003eCHMP\u003c/abbr\u003e opinion has been given, evidence of this should be provided to the MHRA, including if available a copy of the final assessment report, along with any required dossier updates which have occurred during the assessment process. The MHRA will determine the national variation based on the available information according to the recognition route.\u003c/p\u003e\n\n\u003ch2 id=\"approach-to-variations-to-converted-eu-mas-applied-for-from-1-january-2021\"\u003e9.\tApproach to variations to converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e applied for from 1 January 2021\u003c/h2\u003e\n\n\u003cp\u003eThis advice applies where the holder of a converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e has notified the \u003cabbr title=\"European Medicines Agency\"\u003eEMA\u003c/abbr\u003e of, or applied to the \u003cabbr title=\"European Medicines Agency\"\u003eEMA\u003c/abbr\u003e for, a variation of the \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e from 1 January 2021 either before or after the data submission date and intends the variation to be made in relation to the converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e.\u003c/p\u003e\n\n\u003ch3 id=\"type-ia-variations\"\u003eType IA Variations\u003c/h3\u003e\n\u003cp\u003eFor minor variations of Type IA  these may be implemented in relation to the converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e at the same time as they are implemented in relation to the corresponding \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e. The variation must be included in the initiating sequence submission as if it had already been accepted in Great Britain.\u003c/p\u003e\n\n\u003cp\u003eThe \u003cabbr title=\"Marketing Authorisation Holder\"\u003eMAH\u003c/abbr\u003e must inform the MHRA when submitting the sequence if the variation was rejected by the \u003cabbr title=\"European Medicines Agency\"\u003eEMA\u003c/abbr\u003e from 1 January 2021 but before the data submission date, and the variation must be removed from the initiating sequence.\u003c/p\u003e\n\n\u003cp\u003eThe variation will be deemed to be accepted unless the holder of the converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e is notified, within 30 days of the data submission date, that it has been rejected.\u003c/p\u003e\n\n\u003cp\u003eThe details of the variation must be included in the summary of historical regulatory activity submitted with the initiating sequence.\u003c/p\u003e\n\n\u003cp\u003eAny Type IA variation submitted after the baseline submission will be processed in accordance with MHRA practice.\u003c/p\u003e\n\n\u003ch3 id=\"type-ib-and-type-ii-variations\"\u003eType IB and Type II Variations\u003c/h3\u003e\n\n\u003cp\u003eFor minor variations of type IB, and major variations of type II, if the variation has not been rejected by the \u003cabbr title=\"European Medicines Agency\"\u003eEMA\u003c/abbr\u003e before the data submission date, a copy of the variation application must be included in the data submission package as a separate \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e sequence (sequence 0001 and so on). The variation will only be considered after the baseline is processed.\u003c/p\u003e\n\n\u003cp\u003eType IB/II variations will be reviewed by MHRA and \u003ca href=\"https://www.gov.uk/government/publications/mhra-fees/current-mhra-fees\" class=\"govuk-link\"\u003ethe appropriate fee will apply\u003c/a\u003e.\u003c/p\u003e\n\n\u003ch4 id=\"pending-variations-at-the-time-of-baseline-submission\"\u003ePending variations at the time of baseline submission\u003c/h4\u003e\n\n\u003cp\u003eSee relevant text in section 7 under Type II variations, where the same approaches can be followed i.e. the variations can be put on hold pending approval of the corresponding centralised variation.\u003c/p\u003e\n\n\u003ch4 id=\"new-variations-submitted-after-the-baseline-submission-has-been-processed\"\u003eNew variations submitted after the baseline submission has been processed\u003c/h4\u003e\n\n\u003cp\u003eIf the identical changes have already been approved for the corresponding centralised product and provided evidence of this is included when the submission is made to the MHRA, the variations will be processed under the recognition route.\u003c/p\u003e\n\n\u003cp\u003eThe table at the bottom of this page provides a summary of the approach to variations that MHRA will take in the different scenarios which may arise.\u003c/p\u003e\n\n\u003ch2 id=\"general-approach-to-renewals-to-converted-eu-mas-from-1-january-2021\"\u003e10. General approach to renewals to converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e from 1 January 2021\u003c/h2\u003e\n\n\u003cp\u003eFor the purpose of renewals, converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e are treated as if they were granted on the date on which the corresponding \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e was granted. The converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e will therefore have the same renewal date in the UK as in the \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e. In general, the MHRA will not consider renewals to converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e before at least a minimal initiating sequence (as defined in section 5) and related documentation (the “data submission package”) has been received.  The date on which the minimal or full initiating sequence is received is referred to as “the data submission date”.\u003c/p\u003e\n\n\u003cp\u003eIn exceptional circumstances, we may consider a renewal (for either a converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e or converted conditional \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e) before the data submission date (in the absence of a minimal or fully initiating sequence) where:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ethe renewal is necessary on urgent safety grounds\u003c/li\u003e\n  \u003cli\u003ethe renewal is necessary in order to maintain supplies of a particular medicinal product to patients in Great Britain\u003c/li\u003e\n  \u003cli\u003ethere are other necessary or beneficial reasons for considering the renewal in advance of receipt of the baseline information\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eIf the holder of a converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e considers that these conditions may apply, they should contact the agency’s \u003ca href=\"https://www.gov.uk/guidance/contact-mhra#regulatory-information-service-ris\" class=\"govuk-link\"\u003eRegulatory Information Service\u003c/a\u003e to ask for agreement from MHRA and to discuss how to proceed.\u003c/p\u003e\n\n\u003cp\u003eRenewal applications may be included with the data submission package as separate \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e sequences in line with the normal national \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e renewal process, but will only be considered after the baseline is processed.\u003c/p\u003e\n\n\u003cp\u003eAfter the data submission date, the normal renewal application process for national \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e and fees will apply.\u003c/p\u003e\n\n\u003ch2 id=\"approach-to-renewals-submitted-to-the-ema-but-not-granted-before-1-january-2021\"\u003e11. Approach to Renewals submitted to the \u003cabbr title=\"European Medicines Agency\"\u003eEMA\u003c/abbr\u003e but not granted before 1 January 2021\u003c/h2\u003e\n\n\u003ch3 id=\"converted-eu-mas\"\u003eConverted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e\n\u003c/h3\u003e\n\u003cp\u003eThis section applies where the holder of a converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e has made an application to the \u003cabbr title=\"European Medicines Agency\"\u003eEMA\u003c/abbr\u003e for a renewal of the \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e before 1 January 2021 but no final decision was made by the \u003cabbr title=\"European Medicines Agency\"\u003eEMA\u003c/abbr\u003e before 1 January 2021.\u003c/p\u003e\n\n\u003cp\u003eA copy of the renewal application must be included in the data submission package as a separate \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e sequence (sequence 0001 and so on). The renewal will only be considered after the baseline is processed\u003c/p\u003e\n\n\u003cp\u003eIn considering the application:\u003c/p\u003e\n\n\u003cp\u003eWhere before 1 January 2021, the \u003cabbr title=\"Committee for Medicinal products for Human Use\"\u003eCHMP\u003c/abbr\u003e has given a positive final opinion and the UK concurred, the renewal will be treated as accepted:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ethe renewal must be included within the initiating sequence submission as if it had already been accepted in Great Britain\u003c/li\u003e\n  \u003cli\u003ethe details of the renewal must be included in the summary of historical regulatory activity submitted with the initiating sequence\u003c/li\u003e\n  \u003cli\u003eno fee will apply for these renewals\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eIf, before 1 January 2021, the renewal had not reached \u003cabbr title=\"Committee for Medicinal products for Human Use\"\u003eCHMP\u003c/abbr\u003e opinion and was in clock-stop following a request for further information:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ea copy of the renewal application must be included in the data submission package as a separate \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e sequence (sequence 0001 and so on)\u003c/li\u003e\n  \u003cli\u003ethe renewal will only be considered after the initiating sequence is processed\u003c/li\u003e\n  \u003cli\u003eno fee will apply for these renewals\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eIf before 1 January 2021 the renewal had not reached \u003cabbr title=\"Committee for Medicinal products for Human Use\"\u003eCHMP\u003c/abbr\u003e opinion and was before clock stop:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ea copy of the renewal application must be included in the data submission package as a separate \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e sequence (sequence 0001 and so on).\u003c/li\u003e\n  \u003cli\u003ethe renewal will only be considered after the initiating sequence is processed.\u003c/li\u003e\n  \u003cli\u003ethe \u003ca href=\"https://www.gov.uk/government/publications/mhra-fees/current-mhra-fees\" class=\"govuk-link\"\u003eappropriate fee will apply\u003c/a\u003e for these renewals and the renewal will be reviewed by the MHRA.\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eWhere, before 1 January 2021, the \u003cabbr title=\"Committee for Medicinal products for Human Use\"\u003eCHMP\u003c/abbr\u003e had given a negative final opinion or had given a positive final opinion but the UK had recorded a divergent opinion, the renewal will be considered in line with normal MHRA practice:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ea copy of the renewal application must be included in the data submission package as a separate \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e sequence (sequence 0001 and so on).\u003c/li\u003e\n  \u003cli\u003ethe renewal will only be considered after the initiating sequence is processed.\u003c/li\u003e\n  \u003cli\u003ethe \u003ca href=\"https://www.gov.uk/government/publications/mhra-fees/current-mhra-fees\" class=\"govuk-link\"\u003eappropriate fee will apply\u003c/a\u003e for these renewals\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003ch3 id=\"converted-conditional-eu-mas\"\u003eConverted conditional \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e\n\u003c/h3\u003e\n\n\u003cp\u003eThis section applies where the holder of a converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e which was granted as a conditional \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e has made an application to the \u003cabbr title=\"European Medicines Agency\"\u003eEMA\u003c/abbr\u003e for a Renewal of the \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e before 1 January 2021 but no final decision has been made by the \u003cabbr title=\"European Medicines Agency\"\u003eEMA\u003c/abbr\u003e before 1 January 2021.\u003c/p\u003e\n\n\u003cp\u003eA copy of the renewal application must be included in the data submission package as a separate \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e sequence (sequence 0001 and so on). The renewal will only be considered after the baseline is processed.\u003c/p\u003e\n\n\u003cp\u003eIn considering the application:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ewhere, before 1 January 2021, the \u003cabbr title=\"Committee for Medicinal products for Human Use\"\u003eCHMP\u003c/abbr\u003e had given a positive final opinion and the UK concurred, the renewal will be treated as accepted\u003c/li\u003e\n  \u003cli\u003ewhere, before 1 January 2021, the \u003cabbr title=\"Committee for Medicinal products for Human Use\"\u003eCHMP\u003c/abbr\u003e had not given an opinion or had given a negative final opinion or had given a positive final opinion but the UK recorded a divergent opinion, the renewal will be reviewed by the MHRA\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003ch2 id=\"approach-to-applications-for-renewals-made-from-1-january-2021\"\u003e12. Approach to applications for renewals made from 1 January 2021\u003c/h2\u003e\n\n\u003ch3 id=\"converted-eu-mas-1\"\u003eConverted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e\n\u003c/h3\u003e\n\n\u003cp\u003eThis section applies where the holder of a converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e is due to make an application for a Renewal of a converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e during the period of one year following 1 January 2021.\u003c/p\u003e\n\n\u003cp\u003eWhere this applies, the \u003cabbr title=\"Marketing Authorisation Holder\"\u003eMAH\u003c/abbr\u003e must submit an application for renewal in accordance with the usual time limits. The application should be submitted as a separate \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e sequence (sequence 0001 and so on) along with the initiating sequence (minimal or complete) if this has not already been submitted. The renewal will only be considered after the baseline is processed.\u003c/p\u003e\n\n\u003cp\u003eThe MHRA will consider the application, which should be accompanied by the appropriate fee.\u003c/p\u003e\n\n\u003cp\u003eThe \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e will remain in force until the MHRA notifies the \u003cabbr title=\"Marketing Authorisation Holder\"\u003eMAH\u003c/abbr\u003e of its decision on the renewal application.\u003c/p\u003e\n\n\u003ch3 id=\"converted-conditional-eu-mas-1\"\u003eConverted conditional \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e\n\u003c/h3\u003e\n\n\u003cp\u003eThis section applies where the holder of a converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e that was granted as a conditional \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e is due to make an application for a Renewal of the \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e during the period of one year following 1 January 2021 and ending on the data submission date.\u003c/p\u003e\n\n\u003cp\u003eWhere this applies, the \u003cabbr title=\"Marketing Authorisation Holder\"\u003eMAH\u003c/abbr\u003e must submit an application for renewal in accordance with the usual time limits, and the application should be submitted as a separate \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e sequence (sequence 0001 and so on) along with the initiating sequence (minimal or complete) if this has not already been submitted. The renewal will only be considered after the baseline is processed.\u003c/p\u003e\n\n\u003cp\u003eThe MHRA will consider the application in accordance with new regulation 66B. No fee is due.\u003c/p\u003e\n\n\u003cp\u003eThe \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e will remain in force until the MHRA notifies the \u003cabbr title=\"Marketing Authorisation Holder\"\u003eMAH\u003c/abbr\u003e of its decision on the renewal application.\u003c/p\u003e\n\n\u003ch2 id=\"general-approach-to-article-613-notifications-for-converted-eu-mas-from-1-january-2021\"\u003e13. General approach to Article 61(3) notifications for converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e from 1 January 2021\u003c/h2\u003e\n\n\u003cp\u003eIn general, the MHRA will not consider Article 61(3) notifications for converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e before at least a minimal initiating sequence (as defined in section 5) and related documentation (the “data submission package”) has been received. In exceptional circumstances we may consider an Article 61(3) notification before the data submission date and in the absence of a minimal or full initiating sequence, if we are of the view that:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ethe notification is necessary on urgent safety grounds\u003c/li\u003e\n  \u003cli\u003ethe notification is necessary in order to maintain supplies of a particular medicinal product to patients in Great Britain or\u003c/li\u003e\n  \u003cli\u003ethere are other necessary or beneficial reasons for considering the variation in advance of receipt of the baseline information.\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eIf the holder of a converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e considers that these conditions may apply, they should contact the agency’s \u003ca href=\"https://www.gov.uk/guidance/contact-mhra#customer-services\" class=\"govuk-link\"\u003eCustomer Service Centre\u003c/a\u003e to ask for agreement from MHRA and discuss how to proceed.\u003c/p\u003e\n\n\u003cp\u003eArticle 61(3) notifications may be included with the data submission package as separate \u003cabbr title=\"electronic Common Technical Document\"\u003eeCTD\u003c/abbr\u003e sequences in line with the normal national \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e notification process but will only be considered after the baseline is processed.\u003c/p\u003e\n\n\u003cp\u003eAfter the data submission date, the normal Article 61(3) process for national \u003cabbr title=\"Marketing Authorisations\"\u003eMAs\u003c/abbr\u003e and fees will apply.\u003c/p\u003e\n\n\u003ch2 id=\"approach-to-article-613-notifications-submitted-to-the-ema-but-not-granted-before-1-january-2021\"\u003e14. Approach to Article 61(3) notifications submitted to the \u003cabbr title=\"European Medicines Agency\"\u003eEMA\u003c/abbr\u003e but not granted before 1 January 2021\u003c/h2\u003e\n\n\u003cp\u003eWhere:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ethe holder of a converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e has made an Article 61(3) notification for the corresponding \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e before 1 January 2021,\u003c/li\u003e\n  \u003cli\u003ethe change is applicable to the product information intended for the UK market,\u003c/li\u003e\n  \u003cli\u003ethe 90-day period referred to in Article 61(3) has not elapsed,\u003c/li\u003e\n  \u003cli\u003ethe \u003cabbr title=\"European Medicines Agency\"\u003eEMA\u003c/abbr\u003e has not objected to the change,\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003ethe notification must be included within the initiating sequence submission as if it had already been accepted in Great Britain. The change may be put in effect at the same time as for the \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e.\u003c/p\u003e\n\n\u003cp\u003eNo fee will apply for these notifications.\u003c/p\u003e\n\n\u003cp\u003eThe notification will be deemed to be accepted unless the holder of the converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e is notified that it has been rejected within 30 days of the data submission date.\u003c/p\u003e\n\n\u003cp\u003eThe details of the Article 61(3) notification must be included in the summary of historical regulatory activity submitted with the initiating sequence and the \u003cabbr title=\"Marketing Authorisation Holder\"\u003eMAH\u003c/abbr\u003e must notify the MHRA if the \u003cabbr title=\"European Medicines Agency\"\u003eEMA\u003c/abbr\u003e rejects the notification from 1 January 2021 but before the data submission date.\u003c/p\u003e\n\n\u003ch2 id=\"approach-to-article-613-notifications-made-from-1-january-2021\"\u003e15. Approach to Article 61(3) notifications made from 1 January 2021\u003c/h2\u003e\n\n\u003cp\u003eWhere the holder of a converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e has made an Article 61(3) notification for the \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e from 1 January 2021 but before the data submission date, and the change is applicable to the product information intended for the Great Britain market, the notification must be included within the initiating sequence submission as if it had already been accepted in Great Britain. The change may be put in effect at the same time as for the \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e.\u003c/p\u003e\n\n\u003cp\u003eNo fee will apply for these notifications.\u003c/p\u003e\n\n\u003cp\u003eThe notification will be deemed to be accepted unless the holder of the converted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e \u003cabbr title=\"Marketing Authorisation\"\u003eMA\u003c/abbr\u003e is notified that it has been rejected within 30 days of the data submission date.\u003c/p\u003e\n\n\u003ch2 id=\"legal-presence-requirement\"\u003e16. Legal presence requirement\u003c/h2\u003e\n\n\u003cp\u003eThe marketing authorisation holder for a UK marketing authorisation (\u003cabbr title=\"Marketing Authorisation Holder\"\u003eMAH\u003c/abbr\u003e) must be established in the UK (Great Britain or Northern Ireland) or in the \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e/EEA. A UK marketing authorisation is one that is granted by the UK Licensing Authority to permit the sale or supply of a product in Great Britain, Northern Ireland or in both territories.\u003c/p\u003e\n\n\u003cp\u003e\u003cabbr title=\"Marketing Authorisation Holders\"\u003eMAHs\u003c/abbr\u003e have the option if they intend to do a Change of Ownership application to:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003einclude the \u003cabbr title=\"Change of Ownership application\"\u003eCOA\u003c/abbr\u003e in the initiating sequence as if it had already been approved by the MHRA and state in the cover letter that this option had been adopted or\u003c/li\u003e\n  \u003cli\u003esubsequently submit a Change of Ownership application (\u003cabbr title=\"Change of Ownership application\"\u003eCOA\u003c/abbr\u003e) after the submission of the baseline initiating sequence\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003e\u003cabbr title=\"Marketing Authorisation Holders\"\u003eMAHs\u003c/abbr\u003e  must ask for PLGB numbers to be issued for the UK \u003cabbr title=\"Marketing Authorisation Holder\"\u003eMAH\u003c/abbr\u003e by requesting them from \u003ca href=\"mailto:Capconversion@mhra.gov.uk\" class=\"govuk-link\"\u003eCapconversion@mhra.gov.uk\u003c/a\u003e and use them in the \u003cabbr title=\"electronic Application Form\"\u003eeAF\u003c/abbr\u003e and the initiating sequence. The initiating sequence must contain the current granted \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e patient information and, additionally, mock-ups of the UK patient information should be included or text-only versions.\u003c/p\u003e\n\n\u003cp\u003eIf text-only versions are provided, the \u003cabbr title=\"Marketing Authorisation Holder\"\u003eMAH\u003c/abbr\u003e will need to submit a subsequent variation to approve mock-ups of the UK patient information within 2 years from 1 January 2021 (by 1 January 2023).\u003c/p\u003e\n\n\u003cp\u003eThe MHRA would prefer that \u003cabbr title=\"Marketing Authorisation Holders\"\u003eMAHs\u003c/abbr\u003e took the former approach and included the change in the initiating sequence. There will be no fee.\u003c/p\u003e\n\n\u003cp\u003eFor \u003cabbr title=\"Marketing Authorisation Holders\"\u003eMAHs\u003c/abbr\u003e who choose to submit a \u003cabbr title=\"Change of Ownership application\"\u003eCOA\u003c/abbr\u003e should see our \u003ca href=\"https://www.gov.uk/guidance/medicines-marketing-authorisation-transfer-ownership\" class=\"govuk-link\"\u003einformation on change of ownership published on our website\u003c/a\u003e.\u003c/p\u003e\n\n\u003ch2 id=\"summary-of-approach-to-variations\"\u003eSummary of approach to variations\u003c/h2\u003e\n\n\u003cp\u003e\u003cspan class=\"gem-c-attachment-link\"\u003e\n  \u003ca class=\"govuk-link\" href=\"https://assets.publishing.service.gov.uk/media/5feded848fa8f53b7e43fc71/summary_variations_table_pdf.pdf\"\u003eSummary approach to variations\u003c/a\u003e  (\u003cspan class=\"gem-c-attachment-link__attribute\"\u003e\u003cabbr title=\"Portable Document Format\" class=\"gem-c-attachment-link__abbr\"\u003ePDF\u003c/abbr\u003e\u003c/span\u003e, \u003cspan class=\"gem-c-attachment-link__attribute\"\u003e45.2 KB\u003c/span\u003e, \u003cspan class=\"gem-c-attachment-link__attribute\"\u003e4 pages\u003c/span\u003e)\u003c/span\u003e\u003c/p\u003e\n\n\u003ch2 id=\"contact\"\u003eContact\u003c/h2\u003e\n\u003cp\u003eFor further information, please email our Customer Services Centre at \u003ca href=\"mailto:RIS.NA@mhra.gov.uk\" class=\"govuk-link\"\u003eRIS.NA@mhra.gov.uk\u003c/a\u003e. You can also email \u003ca href=\"mailto:capconversion@mhra.gov.uk\" class=\"govuk-link\"\u003ecapconversion@mhra.gov.uk\u003c/a\u003e with urgent questions. Alternatively, contact your Trade Association by emailing:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eAssociation of the British Pharmaceutical Industry (ABPI): \u003ca href=\"mailto:regulatory@abpi.org.uk\" class=\"govuk-link\"\u003eregulatory@abpi.org.uk\u003c/a\u003e\n\u003c/li\u003e\n  \u003cli\u003eBritish Generic Manufacturers Association (BGMA): \u003ca href=\"mailto:info@britishgenerics.co.uk\" class=\"govuk-link\"\u003einfo@britishgenerics.co.uk\u003c/a\u003e\n\u003c/li\u003e\n  \u003cli\u003eBioIndustry Association (BIA): \u003ca href=\"mailto:regulatory@bioindustry.org\" class=\"govuk-link\"\u003eregulatory@bioindustry.org\u003c/a\u003e\n\u003c/li\u003e\n  \u003cli\u003eClinical \u0026amp; Contract Research Association (CCRA): \u003ca href=\"mailto:mail@ccra.org.uk\" class=\"govuk-link\"\u003email@ccra.org.uk\u003c/a\u003e\n\u003c/li\u003e\n  \u003cli\u003eEthical Medicines Industry Group (EMIG): \u003ca href=\"mailto:info@emig.org.uk\" class=\"govuk-link\"\u003einfo@emig.org.uk\u003c/a\u003e\n\u003c/li\u003e\n  \u003cli\u003eHealth Food Manufacturers’ Association (HFMA): \u003ca href=\"mailto:pennyviner@btconnect.com\" class=\"govuk-link\"\u003epennyviner@btconnect.com\u003c/a\u003e\n\u003c/li\u003e\n  \u003cli\u003eThe National Pharmacy Association (NPA): \u003ca href=\"mailto:independentsvoice@npa.co.uk\" class=\"govuk-link\"\u003eindependentsvoice@npa.co.uk\u003c/a\u003e\n\u003c/li\u003e\n  \u003cli\u003eProprietary Association of Great Britain (PAGB): \u003ca href=\"mailto:regulatory@pagb.co.uk\" class=\"govuk-link\"\u003eregulatory@pagb.co.uk\u003c/a\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003c/div\u003e",
                    "change_history":  [
                                           {
                                               "note":  "Addition of further guidance on what to submit if the converted licence should be cancelled in mainland UK between 31 December 2020 and 31 December 2021",
                                               "public_timestamp":  "2021-10-15T12:24:53.000+01:00"
                                           },
                                           {
                                               "note":  "Updated Section 15 on Legal presence requirement to make it clearer.",
                                               "public_timestamp":  "2021-01-05T14:04:19.000+00:00"
                                           },
                                           {
                                               "note":  "First published.",
                                               "public_timestamp":  "2020-12-31T23:01:00.000+00:00"
                                           }
                                       ],
                    "emphasised_organisations":  [
                                                     "240f72bd-9a4d-4f39-94d9-77235cadde8e"
                                                 ],
                    "first_public_at":  "2020-12-31T23:01:00.000+00:00",
                    "political":  false,
                    "related_mainstream_content":  [

                                                   ],
                    "tags":  {
                                 "browse_pages":  [

                                                  ]
                             }
                },
    "document_type":  "detailed_guide",
    "first_published_at":  "2020-12-31T23:01:00+00:00",
    "links":  {
                  "available_translations":  [
                                                 {
                                                     "api_path":  "/api/content/guidance/converting-centrally-authorised-products-caps-to-uk-marketing-authorisations-mas-grandfathering-and-managing-lifecycle-changes",
                                                     "api_url":  "https://www.gov.uk/api/content/guidance/converting-centrally-authorised-products-caps-to-uk-marketing-authorisations-mas-grandfathering-and-managing-lifecycle-changes",
                                                     "base_path":  "/guidance/converting-centrally-authorised-products-caps-to-uk-marketing-authorisations-mas-grandfathering-and-managing-lifecycle-changes",
                                                     "content_id":  "8fa70744-6820-4b33-9823-25ece606ff94",
                                                     "document_type":  "detailed_guide",
                                                     "links":  {

                                                               },
                                                     "locale":  "en",
                                                     "public_updated_at":  "2021-10-15T11:24:53Z",
                                                     "schema_name":  "detailed_guide",
                                                     "title":  "Converting Centrally Authorised Products (CAPs) to UK Marketing Authorisations (MAs), \u0027grandfathering\u0027 and managing lifecycle changes",
                                                     "web_url":  "https://www.gov.uk/guidance/converting-centrally-authorised-products-caps-to-uk-marketing-authorisations-mas-grandfathering-and-managing-lifecycle-changes",
                                                     "withdrawn":  false
                                                 }
                                             ],
                  "document_collections":  [
                                               {
                                                   "api_path":  "/api/content/government/collections/new-guidance-and-information-for-industry-from-the-mhra",
                                                   "api_url":  "https://www.gov.uk/api/content/government/collections/new-guidance-and-information-for-industry-from-the-mhra",
                                                   "base_path":  "/government/collections/new-guidance-and-information-for-industry-from-the-mhra",
                                                   "content_id":  "aecc31f9-1d53-4c18-9df4-4e5940323c4f",
                                                   "document_type":  "document_collection",
                                                   "links":  {
                                                                 "documents":  [
                                                                                   {
                                                                                       "api_path":  "/api/content/guidance/converting-centrally-authorised-products-caps-to-uk-marketing-authorisations-mas-grandfathering-and-managing-lifecycle-changes",
                                                                                       "api_url":  "https://www.gov.uk/api/content/guidance/converting-centrally-authorised-products-caps-to-uk-marketing-authorisations-mas-grandfathering-and-managing-lifecycle-changes",
                                                                                       "base_path":  "/guidance/converting-centrally-authorised-products-caps-to-uk-marketing-authorisations-mas-grandfathering-and-managing-lifecycle-changes",
                                                                                       "content_id":  "8fa70744-6820-4b33-9823-25ece606ff94",
                                                                                       "document_type":  "detailed_guide",
                                                                                       "links":  {

                                                                                                 },
                                                                                       "locale":  "en",
                                                                                       "public_updated_at":  "2021-10-15T11:24:53Z",
                                                                                       "schema_name":  "detailed_guide",
                                                                                       "title":  "Converting Centrally Authorised Products (CAPs) to UK Marketing Authorisations (MAs), \u0027grandfathering\u0027 and managing lifecycle changes",
                                                                                       "web_url":  "https://www.gov.uk/guidance/converting-centrally-authorised-products-caps-to-uk-marketing-authorisations-mas-grandfathering-and-managing-lifecycle-changes",
                                                                                       "withdrawn":  false
                                                                                   }
                                                                               ]
                                                             },
                                                   "locale":  "en",
                                                   "public_updated_at":  "2021-03-30T10:06:39Z",
                                                   "schema_name":  "document_collection",
                                                   "title":  "New guidance and information for industry from the MHRA",
                                                   "web_url":  "https://www.gov.uk/government/collections/new-guidance-and-information-for-industry-from-the-mhra",
                                                   "withdrawn":  false
                                               },
                                               {
                                                   "api_path":  "/api/content/government/collections/moving-goods-into-out-of-or-through-northern-ireland",
                                                   "api_url":  "https://www.gov.uk/api/content/government/collections/moving-goods-into-out-of-or-through-northern-ireland",
                                                   "base_path":  "/government/collections/moving-goods-into-out-of-or-through-northern-ireland",
                                                   "content_id":  "a3deaf0f-3161-40a1-b122-02d016fcb526",
                                                   "document_type":  "document_collection",
                                                   "links":  {
                                                                 "documents":  [
                                                                                   {
                                                                                       "api_path":  "/api/content/guidance/converting-centrally-authorised-products-caps-to-uk-marketing-authorisations-mas-grandfathering-and-managing-lifecycle-changes",
                                                                                       "api_url":  "https://www.gov.uk/api/content/guidance/converting-centrally-authorised-products-caps-to-uk-marketing-authorisations-mas-grandfathering-and-managing-lifecycle-changes",
                                                                                       "base_path":  "/guidance/converting-centrally-authorised-products-caps-to-uk-marketing-authorisations-mas-grandfathering-and-managing-lifecycle-changes",
                                                                                       "content_id":  "8fa70744-6820-4b33-9823-25ece606ff94",
                                                                                       "document_type":  "detailed_guide",
                                                                                       "links":  {

                                                                                                 },
                                                                                       "locale":  "en",
                                                                                       "public_updated_at":  "2021-10-15T11:24:53Z",
                                                                                       "schema_name":  "detailed_guide",
                                                                                       "title":  "Converting Centrally Authorised Products (CAPs) to UK Marketing Authorisations (MAs), \u0027grandfathering\u0027 and managing lifecycle changes",
                                                                                       "web_url":  "https://www.gov.uk/guidance/converting-centrally-authorised-products-caps-to-uk-marketing-authorisations-mas-grandfathering-and-managing-lifecycle-changes",
                                                                                       "withdrawn":  false
                                                                                   }
                                                                               ]
                                                             },
                                                   "locale":  "en",
                                                   "public_updated_at":  "2021-01-07T00:00:00Z",
                                                   "schema_name":  "document_collection",
                                                   "title":  "Moving goods into, out of, or through Northern Ireland",
                                                   "web_url":  "https://www.gov.uk/government/collections/moving-goods-into-out-of-or-through-northern-ireland",
                                                   "withdrawn":  false
                                               }
                                           ],
                  "government":  [
                                     {
                                         "api_path":  "/api/content/government/2015-conservative-government",
                                         "api_url":  "https://www.gov.uk/api/content/government/2015-conservative-government",
                                         "base_path":  "/government/2015-conservative-government",
                                         "content_id":  "d4fbc1b9-d47d-4386-af04-ac909f868f92",
                                         "details":  {
                                                         "current":  false,
                                                         "ended_on":  "2016-07-13T00:00:00+00:00",
                                                         "started_on":  "2015-05-08T00:00:00+00:00"
                                                     },
                                         "document_type":  "government",
                                         "links":  {

                                                   },
                                         "locale":  "en",
                                         "title":  "2015 to 2016 Cameron Conservative government",
                                         "web_url":  "https://www.gov.uk/government/2015-conservative-government"
                                     }
                                 ],
                  "organisations":  [
                                        {
                                            "analytics_identifier":  "EA63",
                                            "api_path":  "/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                            "api_url":  "https://www.gov.uk/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                            "base_path":  "/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                            "content_id":  "240f72bd-9a4d-4f39-94d9-77235cadde8e",
                                            "details":  {
                                                            "acronym":  "MHRA",
                                                            "brand":  "department-of-health",
                                                            "default_news_image":  null,
                                                            "logo":  {
                                                                         "crest":  "single-identity",
                                                                         "formatted_title":  "Medicines \u0026amp; Healthcare products\u003cbr/\u003eRegulatory Agency"
                                                                     },
                                                            "organisation_govuk_status":  {
                                                                                              "status":  "live",
                                                                                              "updated_at":  null,
                                                                                              "url":  null
                                                                                          }
                                                        },
                                            "document_type":  "organisation",
                                            "links":  {

                                                      },
                                            "locale":  "en",
                                            "schema_name":  "organisation",
                                            "title":  "Medicines and Healthcare products Regulatory Agency",
                                            "web_url":  "https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                            "withdrawn":  false
                                        }
                                    ],
                  "original_primary_publishing_organisation":  [
                                                                   {
                                                                       "analytics_identifier":  "EA63",
                                                                       "api_path":  "/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                                       "api_url":  "https://www.gov.uk/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                                       "base_path":  "/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                                       "content_id":  "240f72bd-9a4d-4f39-94d9-77235cadde8e",
                                                                       "details":  {
                                                                                       "acronym":  "MHRA",
                                                                                       "brand":  "department-of-health",
                                                                                       "default_news_image":  null,
                                                                                       "logo":  {
                                                                                                    "crest":  "single-identity",
                                                                                                    "formatted_title":  "Medicines \u0026amp; Healthcare products\u003cbr/\u003eRegulatory Agency"
                                                                                                },
                                                                                       "organisation_govuk_status":  {
                                                                                                                         "status":  "live",
                                                                                                                         "updated_at":  null,
                                                                                                                         "url":  null
                                                                                                                     }
                                                                                   },
                                                                       "document_type":  "organisation",
                                                                       "links":  {

                                                                                 },
                                                                       "locale":  "en",
                                                                       "schema_name":  "organisation",
                                                                       "title":  "Medicines and Healthcare products Regulatory Agency",
                                                                       "web_url":  "https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                                       "withdrawn":  false
                                                                   }
                                                               ],
                  "primary_publishing_organisation":  [
                                                          {
                                                              "analytics_identifier":  "EA63",
                                                              "api_path":  "/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                              "api_url":  "https://www.gov.uk/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                              "base_path":  "/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                              "content_id":  "240f72bd-9a4d-4f39-94d9-77235cadde8e",
                                                              "details":  {
                                                                              "acronym":  "MHRA",
                                                                              "brand":  "department-of-health",
                                                                              "default_news_image":  null,
                                                                              "logo":  {
                                                                                           "crest":  "single-identity",
                                                                                           "formatted_title":  "Medicines \u0026amp; Healthcare products\u003cbr/\u003eRegulatory Agency"
                                                                                       },
                                                                              "organisation_govuk_status":  {
                                                                                                                "status":  "live",
                                                                                                                "updated_at":  null,
                                                                                                                "url":  null
                                                                                                            }
                                                                          },
                                                              "document_type":  "organisation",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "schema_name":  "organisation",
                                                              "title":  "Medicines and Healthcare products Regulatory Agency",
                                                              "web_url":  "https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                              "withdrawn":  false
                                                          }
                                                      ],
                  "suggested_ordered_related_items":  [
                                                          {
                                                              "api_path":  "/api/content/guidance/guidance-on-the-handling-of-applications-for-centrally-authorised-products-caps",
                                                              "api_url":  "https://www.gov.uk/api/content/guidance/guidance-on-the-handling-of-applications-for-centrally-authorised-products-caps",
                                                              "base_path":  "/guidance/guidance-on-the-handling-of-applications-for-centrally-authorised-products-caps",
                                                              "content_id":  "0508124b-9a5a-4253-b678-beb021619c1f",
                                                              "document_type":  "detailed_guide",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "public_updated_at":  "2020-12-31T23:01:00Z",
                                                              "schema_name":  "detailed_guide",
                                                              "title":  "Guidance on the handling of applications for Centrally Authorised Products (CAPs)",
                                                              "web_url":  "https://www.gov.uk/guidance/guidance-on-the-handling-of-applications-for-centrally-authorised-products-caps",
                                                              "withdrawn":  false
                                                          },
                                                          {
                                                              "api_path":  "/api/content/guidance/renewing-marketing-authorisations-for-medicines",
                                                              "api_url":  "https://www.gov.uk/api/content/guidance/renewing-marketing-authorisations-for-medicines",
                                                              "base_path":  "/guidance/renewing-marketing-authorisations-for-medicines",
                                                              "content_id":  "08eccb7e-18cd-45ae-b405-981a09389dfb",
                                                              "document_type":  "detailed_guide",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "public_updated_at":  "2024-12-31T12:31:22Z",
                                                              "schema_name":  "detailed_guide",
                                                              "title":  "Renewing marketing authorisations for medicines",
                                                              "web_url":  "https://www.gov.uk/guidance/renewing-marketing-authorisations-for-medicines",
                                                              "withdrawn":  false
                                                          },
                                                          {
                                                              "api_path":  "/api/content/guidance/medicines-marketing-authorisation-transfer-ownership",
                                                              "api_url":  "https://www.gov.uk/api/content/guidance/medicines-marketing-authorisation-transfer-ownership",
                                                              "base_path":  "/guidance/medicines-marketing-authorisation-transfer-ownership",
                                                              "content_id":  "6027a934-7631-11e4-a3cb-005056011aef",
                                                              "document_type":  "detailed_guide",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "public_updated_at":  "2023-11-17T16:53:14Z",
                                                              "schema_name":  "detailed_guide",
                                                              "title":  "Medicines marketing authorisation: change of ownership",
                                                              "web_url":  "https://www.gov.uk/guidance/medicines-marketing-authorisation-transfer-ownership",
                                                              "withdrawn":  false
                                                          },
                                                          {
                                                              "api_path":  "/api/content/guidance/reference-medicinal-products-rmps",
                                                              "api_url":  "https://www.gov.uk/api/content/guidance/reference-medicinal-products-rmps",
                                                              "base_path":  "/guidance/reference-medicinal-products-rmps",
                                                              "content_id":  "d64bf3fc-32f7-4eea-a298-b6a59683a674",
                                                              "document_type":  "detailed_guide",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "public_updated_at":  "2024-10-18T15:51:46Z",
                                                              "schema_name":  "detailed_guide",
                                                              "title":  "Reference Medicinal Products (RMPs)",
                                                              "web_url":  "https://www.gov.uk/guidance/reference-medicinal-products-rmps",
                                                              "withdrawn":  false
                                                          },
                                                          {
                                                              "api_path":  "/api/content/government/publications/list-of-approved-countries-for-authorised-human-medicines",
                                                              "api_url":  "https://www.gov.uk/api/content/government/publications/list-of-approved-countries-for-authorised-human-medicines",
                                                              "base_path":  "/government/publications/list-of-approved-countries-for-authorised-human-medicines",
                                                              "content_id":  "d165db32-e435-4cf3-9a1f-cdf0d821d883",
                                                              "document_type":  "guidance",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "public_updated_at":  "2021-12-22T15:25:08Z",
                                                              "schema_name":  "publication",
                                                              "title":  "List of approved countries for authorised human medicines",
                                                              "web_url":  "https://www.gov.uk/government/publications/list-of-approved-countries-for-authorised-human-medicines",
                                                              "withdrawn":  false
                                                          }
                                                      ],
                  "taxons":  [
                                 {
                                     "api_path":  "/api/content/health-and-social-care/medicines-medical-devices-blood-marketing-authorisations-variations-licensing",
                                     "api_url":  "https://www.gov.uk/api/content/health-and-social-care/medicines-medical-devices-blood-marketing-authorisations-variations-licensing",
                                     "base_path":  "/health-and-social-care/medicines-medical-devices-blood-marketing-authorisations-variations-licensing",
                                     "content_id":  "f4f28e9d-2050-45fb-ab76-78c0345670da",
                                     "details":  {
                                                     "internal_name":  "Marketing authorisations, variations and licensing guidance [T]",
                                                     "notes_for_editors":  "",
                                                     "visible_to_departmental_editors":  false
                                                 },
                                     "document_type":  "taxon",
                                     "links":  {
                                                   "parent_taxons":  [
                                                                         {
                                                                             "api_path":  "/api/content/health-and-social-care/medicines-medical-devices-blood",
                                                                             "api_url":  "https://www.gov.uk/api/content/health-and-social-care/medicines-medical-devices-blood",
                                                                             "base_path":  "/health-and-social-care/medicines-medical-devices-blood",
                                                                             "content_id":  "cebc01ee-f70a-4397-a552-622e10b62508",
                                                                             "description":  "",
                                                                             "details":  {
                                                                                             "internal_name":  "Medicines and medical devices [T] (level 2, health theme)",
                                                                                             "notes_for_editors":  "",
                                                                                             "visible_to_departmental_editors":  false
                                                                                         },
                                                                             "document_type":  "taxon",
                                                                             "links":  {
                                                                                           "parent_taxons":  [
                                                                                                                 {
                                                                                                                     "api_path":  "/api/content/health-and-social-care",
                                                                                                                     "api_url":  "https://www.gov.uk/api/content/health-and-social-care",
                                                                                                                     "base_path":  "/health-and-social-care",
                                                                                                                     "content_id":  "8124ead8-8ebc-4faf-88ad-dd5cbcc92ba8",
                                                                                                                     "description":  "",
                                                                                                                     "details":  {
                                                                                                                                     "internal_name":  "Health and social care",
                                                                                                                                     "notes_for_editors":  "",
                                                                                                                                     "visible_to_departmental_editors":  true
                                                                                                                                 },
                                                                                                                     "document_type":  "taxon",
                                                                                                                     "links":  {
                                                                                                                                   "root_taxon":  ""
                                                                                                                               },
                                                                                                                     "locale":  "en",
                                                                                                                     "phase":  "live",
                                                                                                                     "public_updated_at":  "2018-09-16T20:30:51Z",
                                                                                                                     "schema_name":  "taxon",
                                                                                                                     "title":  "Health and social care",
                                                                                                                     "web_url":  "https://www.gov.uk/health-and-social-care",
                                                                                                                     "withdrawn":  false
                                                                                                                 }
                                                                                                             ]
                                                                                       },
                                                                             "locale":  "en",
                                                                             "phase":  "live",
                                                                             "public_updated_at":  "2019-02-06T16:16:55Z",
                                                                             "schema_name":  "taxon",
                                                                             "title":  "Medicines, medical devices",
                                                                             "web_url":  "https://www.gov.uk/health-and-social-care/medicines-medical-devices-blood",
                                                                             "withdrawn":  false
                                                                         }
                                                                     ]
                                               },
                                     "locale":  "en",
                                     "phase":  "live",
                                     "public_updated_at":  "2018-08-22T12:56:21Z",
                                     "schema_name":  "taxon",
                                     "title":  "Marketing authorisations, variations and licensing guidance",
                                     "web_url":  "https://www.gov.uk/health-and-social-care/medicines-medical-devices-blood-marketing-authorisations-variations-licensing",
                                     "withdrawn":  false
                                 },
                                 {
                                     "api_path":  "/api/content/government/brexit",
                                     "api_url":  "https://www.gov.uk/api/content/government/brexit",
                                     "base_path":  "/government/brexit",
                                     "content_id":  "d6c2de5d-ef90-45d1-82d4-5f2438369eea",
                                     "description":  "Find out how new Brexit rules apply to things like travel and doing business with Europe.",
                                     "details":  {
                                                     "internal_name":  "Brexit",
                                                     "notes_for_editors":  "",
                                                     "url_override":  "/government/collections/brexit-guidance",
                                                     "visible_to_departmental_editors":  true
                                                 },
                                     "document_type":  "taxon",
                                     "links":  {
                                                   "parent_taxons":  [
                                                                         {
                                                                             "api_path":  "/api/content/government/all",
                                                                             "api_url":  "https://www.gov.uk/api/content/government/all",
                                                                             "base_path":  "/government/all",
                                                                             "content_id":  "e48ab80a-de80-4e83-bf59-26316856a5f9",
                                                                             "description":  "",
                                                                             "details":  {
                                                                                             "internal_name":  "Government",
                                                                                             "notes_for_editors":  "",
                                                                                             "visible_to_departmental_editors":  true
                                                                                         },
                                                                             "document_type":  "taxon",
                                                                             "links":  {
                                                                                           "root_taxon":  [
                                                                                                              {
                                                                                                                  "api_path":  "/api/content/",
                                                                                                                  "api_url":  "https://www.gov.uk/api/content/",
                                                                                                                  "base_path":  "/",
                                                                                                                  "content_id":  "f3bbdec2-0e62-4520-a7fd-6ffd5d36e03a",
                                                                                                                  "document_type":  "homepage",
                                                                                                                  "links":  {

                                                                                                                            },
                                                                                                                  "locale":  "en",
                                                                                                                  "public_updated_at":  "2023-06-28T09:32:34Z",
                                                                                                                  "schema_name":  "homepage",
                                                                                                                  "title":  "GOV.UK homepage",
                                                                                                                  "web_url":  "https://www.gov.uk/",
                                                                                                                  "withdrawn":  false
                                                                                                              }
                                                                                                          ]
                                                                                       },
                                                                             "locale":  "en",
                                                                             "phase":  "live",
                                                                             "public_updated_at":  "2018-09-16T20:29:39Z",
                                                                             "schema_name":  "taxon",
                                                                             "title":  "Government",
                                                                             "web_url":  "https://www.gov.uk/government/all",
                                                                             "withdrawn":  false
                                                                         }
                                                                     ]
                                               },
                                     "locale":  "en",
                                     "phase":  "live",
                                     "public_updated_at":  "2024-11-14T17:47:34Z",
                                     "schema_name":  "taxon",
                                     "title":  "Brexit",
                                     "web_url":  "https://www.gov.uk/government/brexit",
                                     "withdrawn":  false
                                 }
                             ]
              },
    "locale":  "en",
    "phase":  "live",
    "public_updated_at":  "2021-10-15T12:24:53+01:00",
    "publishing_app":  "whitehall",
    "publishing_request_id":  "21-1713893618.032-10.13.28.206-628",
    "publishing_scheduled_at":  "2020-12-31T23:00:00+00:00",
    "rendering_app":  "government-frontend",
    "scheduled_publishing_delay_seconds":  165,
    "schema_name":  "detailed_guide",
    "title":  "Converting Centrally Authorised Products (CAPs) to UK Marketing Authorisations (MAs), \u0027grandfathering\u0027 and managing lifecycle changes",
    "updated_at":  "2024-12-31T12:31:23+00:00",
    "withdrawn_notice":  {

                         }
}
